BELINDA : Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaB-Cell Non Hodgkin Lymphoma,Follicular Lymphoma,Lymphoma

Trial Overview Read MoreRead more

This phase III trial is comparing an immunotherapy to standard of care treatment in adults who have been diagnosed with B-cell Non-Hodgkin Lymphoma and have failed prior immunochemotherapy.
 

This trial is treating patients with B-Cell Non-Hodgkin Lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial

Commercial Sponsor

Novartis Pharmaceuticals

Summary

Eligible patients will be randomised to receive the investigator's choice of optional platinum-based immunochemotherapy followed by (1) lymphodepleting chemotherapy (containing fludarabine with cyclophosphamide or bendamustine) and a single dose of Tisagenlecleucel OR (2, in responding patients only) high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT).

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Enquiries Line Coordinator
clinicaltrials.enquiries@petermac.org
03 8559 7456 (9am-2pm, Mon-Fri)

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next